This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Chemed's (CHE) Q4 revenues grow across key segments.
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
Why Is Abbott (ABT) Up 6% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $75.14 in the latest trading session, marking a -0.53% move from the prior day.
Medidata's (MDSO) Margins Under Pressure, Competition Rife
by Zacks Equity Research
Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
by Zacks Equity Research
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
Align Technology Unveils iTero Element 5D Imaging System
by Zacks Equity Research
Align Technology (ALGN) continues to expand work flow options of iTero scanners.
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
by Zacks Equity Research
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
by Zacks Equity Research
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Baxter's Acute Therapies Profile Strong, Competition Rife
by Zacks Equity Research
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.
Boston Scientific Benefits From New Buyouts & Product Launch
by Zacks Equity Research
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Here's Why Investors Should Retain AmerisourceBergen Stock
by Zacks Equity Research
AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
by Zacks Equity Research
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.